ABL-105 is under clinical development by ABL Bio and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase II drugs for Gastroesophageal (GE) Junction Carcinomas have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ABL-105’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ABL-105 is under development for the treatment of solid tumor including human epidermal growth factor receptor 2 positive breast cancer (her2 positive breast cancer), gastric cancer, gastroesophageal junction carcinomas. The drug candidate is a bi-specific monoclonal antibody. It acts by targeting cells expressing Her2 and Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB). The drug candidate is developed as T cell engager based on Grabody T BsAb Platform.
ABL Bio overview
ABL Bio is a biotechnology company that develops therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Republic of Korea (South Korea).
For a complete picture of ABL-105’s drug-specific PTSR and LoA scores, buy the report here.